# reload+after+2024-01-22 09:43:46.888829
address1§Zeus Building
address2§Unit 6-10 Rutherford Avenue
city§Harwell
zip§OX11 0DF
country§United Kingdom
phone§44 1865 818 808
website§https://www.barinthusbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
fullTimeEmployees§107
companyOfficers§[{'maxAge': 1, 'name': 'Mr. William J. Enright MBA', 'age': 60, 'title': 'CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 916619, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sarah  Gilbert', 'title': 'Co-Founder', 'fiscalYear': 2022, 'totalPay': 48983, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adrian  Hill Ph.D.', 'title': 'Co-Founder & Scientific Advisor', 'fiscalYear': 2022, 'totalPay': 61606, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gemma  Brown', 'age': 33, 'title': 'CFO & Company Secretary', 'yearBorn': 1990, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nadege  Pelletier Ph.D.', 'age': 45, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Graham  Griffiths', 'age': 44, 'title': 'Chief Business Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth  Eagling-Vose M.B.A.', 'title': 'Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Bernie  McDonald', 'title': 'Head of IP', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Geoffrey  Lynn', 'title': 'Senior Vice President of Synthetic Immunotherapies', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard  Parsons', 'title': 'Financial Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.498
priceToSalesTrailing12Months§18.700903
currency§USD
dateShortInterest§1702598400
forwardEps§-2.37
exchange§NGM
quoteType§EQUITY
shortName§Barinthus Biotherapeutics plc
longName§Barinthus Biotherapeutics plc
firstTradeDateEpochUtc§1619789400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§707a043e-fc69-36ad-8b44-afbf6d977172
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§3.0
targetMeanPrice§8.8
targetMedianPrice§7.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§8.95
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
